Market Size of Therapeutic Plasma Exchange Systems Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 7.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Therapeutic Plasma Exchange Market Analysis
The Therapeutic plasma exchange systems market studied was anticipated to grow with a CAGR of nearly 7.5% during the forecast period. The major factor attributing to the growth of the market is an increased number of patients diagnosed with autoimmune diseases, hematology disorders, cardiovascular diseases, and a rise in the geriatric population. For instance, according to the National Institutes of Health report published in the year 2020, the prevalence of myasthenia gravis is increasing in recent decades and affects about 20 per 100,000 people worldwide every year demanding the efficient treatments for the ailments which are likely to fuel the market over the forecast period.
Therapeutic Plasma Exchange Industry Segmentation
Therapeutic plasma exchange (TPE), also known as plasmapheresis is an extracorporeal blood purification technique that removes pathogenic substances such as pathogenic autoantibodies, immune complexes, cryoglobulins and cholesterol-containing lipoproteins from the plasma of patients and replaces with substitution fluid such as albumin solution, or often fresh frozen plasma. TPE is used in the treatment of various autoimmune diseases, renal disorders, hematology disorders, etc, which is likely to drive the growth of the market.
Products | |
Apheresis Machine | |
Filters | |
Others |
Indication | |
Neurological Disorders | |
Cardiovascular Disorders | |
Hematology Disorders | |
Renal Disorders | |
Others |
End-User | |
Hospitals | |
Ambulatory Surgical Centers | |
Others |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Therapeutic Plasma Exchange Systems Market Size Summary
The therapeutic plasma exchange systems market is poised for significant growth, driven by an increasing prevalence of autoimmune diseases, hematology disorders, and cardiovascular conditions, alongside a rising geriatric population. The demand for effective treatments for conditions such as myasthenia gravis is contributing to this expansion. The neurological disorders segment is expected to generate the largest revenue, attributed to the efficacy of therapeutic plasma exchange in managing conditions like Guillain-Barre syndrome and multiple sclerosis. Meanwhile, the cardiovascular disorders segment is projected to experience the highest growth rate, fueled by the adoption of therapeutic plasma exchange as a primary treatment for arteriosclerosis and rheumatic endocarditis. Technological advancements enhancing the application of therapeutic plasma exchange in removing lipoproteins and inflammatory factors are also expected to propel market growth. Hospitals are anticipated to hold the major market share due to the high number of patients with cardiac, neurological, and renal conditions, supported by favorable reimbursement policies and a shift of physicians from private clinics to larger healthcare facilities.
North America is expected to maintain its dominance in the therapeutic plasma exchange systems market, driven by the rising prevalence of autoimmune disorders and the adoption of lipoprotein apheresis treatments for cardiovascular indications. The region's advanced technology and established healthcare infrastructure further bolster market growth. The market is moderately competitive, with key players like Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B. Braun Melsungen AG, and Fresenius Kabi AG actively expanding their market positions through acquisitions, mergers, and the introduction of new treatment methods. Notably, Terumo BCT's receipt of CE mark approval for its Spectra Optia Apheresis System in Europe highlights the ongoing innovation and regulatory advancements within the industry, contributing to the market's revenue share.
Therapeutic Plasma Exchange Systems Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Global Prevalence of Autoimmune and Cardiac Diseases
-
1.2.2 Growing R&D Activities and Clinical Trials to Increase the Application in Various Indications
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Treatment and Devices
-
1.3.2 Lack of Skilled Healthcare Professionals in Emerging Markets
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Products
-
2.1.1 Apheresis Machine
-
2.1.2 Filters
-
2.1.3 Others
-
-
2.2 Indication
-
2.2.1 Neurological Disorders
-
2.2.2 Cardiovascular Disorders
-
2.2.3 Hematology Disorders
-
2.2.4 Renal Disorders
-
2.2.5 Others
-
-
2.3 End-User
-
2.3.1 Hospitals
-
2.3.2 Ambulatory Surgical Centers
-
2.3.3 Others
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United states
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Therapeutic Plasma Exchange Systems Market Size FAQs
What is the current Therapeutic Plasma Exchange Systems Market size?
The Therapeutic Plasma Exchange Systems Market is projected to register a CAGR of greater than 7.5% during the forecast period (2024-2029)
Who are the key players in Therapeutic Plasma Exchange Systems Market?
Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B. Braun Melsungen AG and Fresenius Kabi AG are the major companies operating in the Therapeutic Plasma Exchange Systems Market.